Eptinezumab Endeavors to Maintain Migraine Prevention Progress
April 23rd 2019The chief executive officer of Alder Biopharmaceuticals detailed where the intravenous anti-CGRP treatment will fit into the marketplace and how the migraine prevention therapy will make an impact in treating patients.
New Acute Migraine Co-Primary End Points Provide Positives for Trial Design
April 22nd 2019A review of newly implemented primary end points—pain freedom and most bothersome symptom freedom at 2 hours—used in 8 clinical trials may help to guide future migraine researchers in the design of acute treatment trials.
Integrative Health and Parkinson Disease
April 18th 2019It has been estimated that between 40% and 60% of patients with PD use at least one form of complementary medicine. In this podcast, neurologist Sarah Mulukutla, MD, MPH talks about CAM options for neurologists to discuss with their patients.
Adverse Pregnancy Outcomes in Teriflunomide-Exposed MS Patients Similar to General Population
April 17th 2019Patients with multiple sclerosis who were exposed to teriflunomide during pregnancy experienced similar risks of major birth defects and spontaneous abortions to the general population’s rates of 2% to 4% and 15% to 20%, respectively.
FDA Accepts NDA for Riluzole Oral Film for ALS
April 16th 2019The Aquestive Therapeutics product, marketed as Exservan, was previously granted an orphan drug designation in January 2018. Its NDA is supported by a number of studies which sought to confirm its bioequivalence to its reference listed drug.
Erenumab Efficacious In Episodic Migraine Patients With Prior Treatment Failure
April 16th 2019The study also added to a growing base of findings which suggest that patients who have failed preventive medications prior to trial participation have lower placebo responses, which could have implications for clinical trial design.
Pascal Sati, PhD: Validating the Central Vein Sign in Multiple Sclerosis Diagnosis
April 16th 2019The senior preclinical and clinical imaging scientist at the National Institute of Neurological Disorders and Stroke spoke about the potential of the central vein sign to help improve the time to an accurate diagnosis in MS.
Migraine Days Reduced Long-Term After Galcanezumab Treatment Cessation
April 15th 2019Data from the EVOLVE-1 and EVOLVE-2 phase 3 clinical trials suggest that galcanezumab (Emgality, Eli Lilly) can maintain ≥50% responder rates equivalent to that of placebo while reducing more monthly migraine days for 5 months after halting treatment.
Multiple Sclerosis Misdiagnosis Could Impact One-Fifth of Patients
April 13th 2019Results of a recent real-world study at 2 MS centers have uncovered misdiagnosis rates of 17% and 19%, with patients facing an average time of misdiagnosis of 4 years during which they may be subject to numerous risks due to improper treatment.
Shorter Therapeutic Coma in Refractory Status Epilepticus May Be Safer, More Effective
April 13th 2019A shorter yet deeper therapeutic coma for treatment of refractory status epilepticus may be more effective and safer than the currently recommended therapeutic coma duration of 24 to 48 hours.
Multiple Sclerosis Biomarker NfL Holds Promise as Treatment Monitoring Tool
April 12th 2019Over the course of 2 years, findings revealed that serum NfL levels were significantly higher in patients with evidence of disease activity compared to those with no evidence of disease activity as well as 35 age-matched healthy controls.